| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 293,651 | 510,575 | ||
| Restricted cash | 6,337 | 6,338 | ||
| Short-term investments, available-for-sale | 126,370 | - | ||
| Accounts receivable | 1,861 | 1,859 | ||
| Prepaid expenses and other current assets | 14,602 | 13,019 | ||
| Total current assets | 442,821 | 531,791 | ||
| Property and equipment, net | 293 | 321 | ||
| Finance lease right-of-use asset, net | 0 | 0 | ||
| Operating lease right-of-use asset | 1,795 | 2,120 | ||
| Long-term investments, available-for-sale | 50,159 | - | ||
| Other assets | 23,582 | 95 | ||
| Total assets | 518,650 | 534,327 | ||
| Accounts payable | 4,351 | 2,206 | ||
| Accrued liabilities | 71,349 | 11,054 | ||
| Accrued indirect tax liabilities | 15,073 | 14,935 | ||
| Accrued compensation and benefits | 3,506 | 2,626 | ||
| Current portion of finance lease liability | 0 | 0 | ||
| Current portion of operating lease liability | 1,560 | 1,497 | ||
| Total current liabilities | 95,839 | 32,318 | ||
| Long-term finance lease liability | 0 | 0 | ||
| Long-term operating lease liability | 424 | 836 | ||
| Total liabilities | 96,263 | 33,154 | ||
| Preferred stock | 0 | 0 | ||
| Preferred stock-Series AConvertible Voting Preferred Stock | 0 | 0 | ||
| Preferred stock-Series XConvertible Preferred Stock | 0 | 0 | ||
| Common stock, 0.0001 par value 100,000,000 shares authorized at september30, 2025 and 50,000,000 shares authorized at december31, 2024 29,335,397 shares issued and outstanding at september30, 2025 and 10,946,635 shares issued and outstanding at december31, 2024 | 3 | 2 | ||
| Additional paid-in capital | 1,166,180 | 1,161,627 | ||
| Accumulated other comprehensive loss | -107 | - | ||
| Accumulated deficit | -743,689 | -660,456 | ||
| Total stockholders equity | 422,387 | 501,173 | ||
| Total liabilities and stockholders equity | 518,650 | 534,327 | ||
Cidara Therapeutics, Inc. (CDTX)
Cidara Therapeutics, Inc. (CDTX)